Inventiva S.A.
(NASDAQ: IVA)
|
5:30 PM UTC, 07/03/24 | |||
---|---|---|---|---|
Last: $2.97 | Change: +0.12 | %Change: +4.21% | Volume: 1,685 |
Open: | $ 2.85 | Volume: | 1,685 | |
---|---|---|---|---|
High: | $ 2.97 | Yield(%) | 0.00 | |
Low: | $ 2.85 | P/E Ratio (ttm): | n/a | |
Dividend ($): | n/a | Market Cap ($): | 149.26M | |
EPS ($) | -0.26 | Shares Out: | 52.37M |
% Price Change (last 4 weeks): | -19.72 |
---|---|
% Price Change (last 13 weeks): | -21.49 |
% Price Change (last 26 weeks): | -39.29 |
% Price Change (last 52 weeks): | -27.85 |
% Price Change (year to date): | -36.89 |
Return on Equity (%): | -1928.18 |
---|---|
Return on Assets (%): | -119.46 |
Return on Invested Capital (%): | -101.49 |
Gross Profit Margin (%): | n/a |
---|---|
Net Profit Margin (%): | -631.84 |
Operating Profit Margin (%): | -618.00 |
|
|
50-day Moving Average: | $3.25 |
---|---|
200-day Moving Average: | $3.77 |
Avg. Daily Vol. (last 50 days): | 12,102 |
Avg. Daily Vol. (last 200 days): | 21,155 |
52-wk high: | $4.75 |
52-wk low: | $2.52 |
Bid: | $2.90 |
Ask: | $2.98 |
Inventiva SA is a clinical-stage biopharmaceutical company, which focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis, or NASH, and other diseases with significant unmet medical need. It owns an in-house drug-discovery platform that develops internal oncology and fibrosis discovery pipeline with approaches centered on transcription factors, epigenetics targets, and nuclear receptors. The company was founded by Pierre Broqua and Frédéric Cren on October 27, 2011 and is headquartered in Daix, France.
|
Inventiva S.A.
50, rue de Dijon Daix BF 21121 Phone: 33.3.80.44.75.00 Fax: n/a http://www.inventivapharma.com |
Earnings (1year) ($): | -2.63 |
---|---|
Annual Dividend ($): | 0.00 |
Current P/E Ratio (ttm): | n/a |
Book Value ($): | -0.69 |
Cash Flow ($): | -2.24 |
Price/Earnings (x): | n/a |
---|---|
Price/Sales (x): | 10.84 |
Price/Book (x): | n/a |
Price/Cash Flow (x): | n/a |
Quick Ratio (x): | 0.94 |
---|---|
Current Ratio (x): | 0.95 |
LT Debt/Equity (x): | n/a |
Total Debt/Equity (x): | n/a |